Few industrial communities in New England have undergone a transformation as dramatic as Devens. The closure of Fort Devens created a unique enterprise zone — with infrastructure, utilities, and land capacity that would cost hundreds of millions to replicate — that has become home to some of the region’s most significant pharmaceutical and biotechnology manufacturing operations. MilliporeSigma (Merck KGaA) operates a major filtration technology R&D and manufacturing facility here. Bristol Myers Squibb operates a significant biologics manufacturing presence at Devens. Olympus Surgical Technologies America maintains precision manufacturing operations at Devens. Emergent BioSolutions has operated significant biologics manufacturing capacity at this location. Veranova has established its global headquarters and FDA-approved center of excellence for antibody-drug conjugate (ADC) and high-potent API manufacturing at Devens, currently undergoing a $30 million capability expansion. King Street Properties’ 45-acre speculative biomanufacturing campus — the first of its kind in the region — further cements Devens as a destination for life science companies scaling out of the Greater Boston research corridor.

Devens cleanrooms reflect the scale and sophistication of the manufacturing operations they support. These are commercial-scale GMP manufacturing environments — not early-stage research labs — with HVAC infrastructure, classified zone architecture, and regulatory oversight commensurate with the products being made. The contamination control standards here are among the most demanding in New England, and the cleaning partner must be equal to those demands.